Results 181 to 190 of about 9,301 (205)

Raltegravir

Drugs, 2008
* Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new cells.
Jamie D, Croxtall, Katherine A, Lyseng-Williamson, Caroline M, Perry   +2 more
openaire   +2 more sources

The Effect of Raltegravir on the Glucuronidation of Lamotrigine

The Journal of Clinical Pharmacology, 2009
The authors studied the effect of raltegravir on the pharmacokinetics of the antiepileptic agent lamotrigine. Twelve healthy volunteers (group A) received 400 mg raltegravir twice daily from days 1 to 5. On day 4, a single dose of 100 mg lamotrigine was administered.
Luin, M. van, Colbers, A., Verwey-van Wissen, C.P.W.G.M., Ewijk-Beneken Kolmer, E.W.J. van, Kolk, M. van der, Hoitsma, A.J., Silva, H.G. da, Burger, D.M.   +7 more
openaire   +4 more sources

Raltegravir-induced DRESS syndrome

Scandinavian Journal of Infectious Diseases, 2012
DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) is a life-threatening adverse drug reaction. Raltegravir is an integrase inhibitor used in HIV-1 infection. We report on a patient who developed a DRESS syndrome under raltegravir treatment, which was identified as a probable case of DRESS on the basis of Kardaun and Naranjo scores.
Olivier Mir, Pierre Loulergue
openaire   +3 more sources

Raltegravir Potassium

Hospital Pharmacy, 2008
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy & Therapeutics Committee. Subscribers also receive monthly 1-page summary monographs on the agents that are useful for agendas and pharmacy/
Dennis J. Cada, Danial E. Baker, Terri Levien   +2 more
openaire   +2 more sources

Effect of Raltegravir on the Pharmacokinetics of Methadone

The Journal of Clinical Pharmacology, 2010
A randomized, placebo‐controlled, 2‐period crossover study in subjects on methadone maintenance therapy was conducted to assess the effect of the HIV‐1 integrase inhibitor, raltegravir, on the pharmacokinetics of methadone. Twelve HIV‐negative male and female subjects stabilized on an oral methadone program were enrolled.
Julie Ann Mabalot Luk, Robert A. Riesenberg, Marian Iwamoto, Jeffery A. Chodakewitz, William D. Hanley, Larissa Wenning, Bo Jin, Matt S. Anderson, John A. Wagner   +8 more
openaire   +3 more sources

Raltegravir resistance in the cerebrospinal fluid

Infection, 2013
We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.
Bruce J. Brew, Borja Mora-Peris, Alan Winston, Nicola Mackie, David A. Cooper, Dan Suan   +5 more
openaire   +3 more sources

Treatment of HIV infection with raltegravir

Expert Opinion on Pharmacotherapy, 2009
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.Data from pharmacokinetic, Phase II and III clinical trials were reviewed ...
Lisa M. Chirch, Roy T. Steigbigel, Sidonie A. Morrison   +2 more
openaire   +3 more sources

Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart

Antiviral Therapy, 2011
Background Raltegravir is the first approved antiretroviral able to prevent HIV genome integration into the host chromosomes. The aim of the study is to test if raltegravir plasma concentrations can be associated with proviral DNA decline during raltegravir-based salvage therapy.
E. Nicastri, C. Tommasi, I. Abbate, BONORA, Stefano, M. Tempestilli, R. Bellagamba, M. Viscione, G. Rozera, A. L. Gallo, J. Ivanovic, A. Amendola, L. Pucillo, DI PERRI, Giovanni, M. R. Capobianchi, P. Narciso   +14 more
openaire   +3 more sources

Raltegravir as antiretroviral therapy in HIV/AIDS

Expert Opinion on Pharmacotherapy, 2013
HIV, a major cause of morbidity and mortality worldwide has been transformed by antiretroviral (ARV) therapy into a manageable condition. Drug resistance, tolerability and drug interactions remain major concerns when choosing ARV therapy. Raltegravir , the first integrase inhibitor in the armamentarium against HIV, has been shown to be efficacious in ...
Sharon Walmsley, Malika Sharma
openaire   +3 more sources